Jowls | Sagging Jawline | Contour & Definition | Fillers - ELLANSÉ®
Go to Patient Section
Go to Physician Section
Brand Blog

What causes sagging jowls?

May 03,2019

As we age, the loss of definition of the jawline, chin and neck are a common source of concern for many men and women. A series of changes occur from around the mid-20s, which leads to an aged appearance. This includes volume loss, loss of structural proteins such as collagen in the skin, and the downwards movement of fat and skin.

These changes are caused by a variety of factors; internal (genetics) and external factors. External factors include activities such as smoking, excess exposure to sun, and weight gain/loss.

Why choose ELLANSÉ®?

ELLANSÉ is a collagen stimulating filler, providing immediate volume restoration and long-term results through the stimulation of collagen production in the skin. This unique dual action will allow you to see results from day one and the results will continue to improve even once the filler has been fully resorbed.

ELLANSÉ can be used throughout the face in a way to positively affect sagging skin along the jawline and chin. By using Ellansé to restore volume in the midface, it can have a lifting effect on some areas of the skin. A more obvious way to improve the definition and contour would be to use Ellansé directly into the jawline and chin. This will immediately regenerate a defined facial structure, and through the stimulation of collagen, this will improve the skin structure and strength for long-lasting results.

  • This facial filler restores volume immediately and gives long-lasting results by stimulating natural collagen production.
  • Results last from at least 1-4* years
  • High patient satisfaction1
  • Used in over 65 countries worldwide.

 *Expected longevity in vivo based extrapolation of clinical data from -S and -M and accepted PCL degradation behaviour


1Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: A 24-month, prospective, randomized, controlled clinical trial. Dermatol Surg 2013;39:457-463


Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Post

Welcome to

Please select the option which best describes you.